logo-loader
viewAllergy Therapeutics PLC

Allergy Therapeutics allowed to hit the reset button on birch pollen phase III trial

“We remain committed to Birch MATA MPL, especially considering the results of the independent secondary endpoint data and the supportive safety profile observed in the B301 study and two successful phase II trials showing significant primary efficacy results," said chief executive Manuel Llobet

Allergy Therapeutics PLC -

Allergy Therapeutics PLC (LON:AGY) has been granted the opportunity to carry out a new phase III clinical study on its short-course birch pollen inoculation after a tranche of data was declared invalid.

In March, it was revealed Birch MATA MPL had failed to reach what in the technical jargon is referred to as its primary endpoint. In layman’s terms it didn’t appear to provide therapeutic value.

However, at the time there Allergy Therapeutics hinted at contradictory results from the study.

Specifically, the researchers found that there was a “highly statistically significant” differences in immunoglobulin markers between the group receiving the treatment and those not that was suggestive of a “sustained immune response”.

The company has since taken advice from the Paul Ehrlich Institute (PEI), the scientific regulator for Germany where the trial was carried out, which has agreed that a new phase III trial can be conducted.

"We are encouraged by our constructive discussions with the PEI who, based upon the clear scientific evidence, decided to invalidate the primary endpoint of the B301 study and agreed to a new pivotal Phase III clinical study for Birch MATA MPL,” Allergy Therapeutics chief executive Manuel Llobet said in a statement.

“We remain committed to Birch MATA MPL, especially considering the results of the independent secondary endpoint data and the supportive safety profile observed in the B301 study and two successful phase II trials showing significant primary efficacy results," he added.

Quick facts: Allergy Therapeutics PLC

Price: 13.63 GBX

AIM:AGY
Market: AIM
Market Cap: £86.86 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Allergy Therapeutics PLC named herein, including the promotion by the Company of Allergy Therapeutics PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Market Report: Coronavirus vaccine update sparks FTSE 100 rally

Headlines from the Proactive UK newsroom. The FTSE 100 rallied 60 points to 6,240 on COVID-19 vaccine hopes. US group Moderna’s early stage trial of a coronavirus vaccine proved safe and sparked some immune response. UK inflation picked up to 0.6% led by demand for online computer games...

2 weeks, 6 days ago

2 min read